Finalising a review of the safety and efficacy of dextropropoxyphene-containing medicines, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that their risks, particularly the risk of potentially fatal overdose, are greater than their benefits. The Committee therefore recommended that the marketing authorisations for these medicines be withdrawn across the European Union. The withdrawal will be gradual to allow time for the safe transfer of patients to appropriate alternative therapies, in line with national recommendations. Dextropropoxyphene is a painkiller used to treat acute and chronic pain.
A marker in the blood of both cats and humans that was identified in a recent study might signal both species' susceptibility for a painful bladder disorder called interstitial cystitis, a condition that is often difficult to diagnose. Follow-up studies of the chemicals that appeared in blood samples suggest that the way tryptophan, an essential amino acid, is processed in cats and humans with interstitial cystitis ultimately could affect the way signals are transmitted in the brain. The results, while preliminary, suggest that the disease is not just a malfunction of the bladder, but might instead have origins in the central nervous system, researchers say.
NUCYNTA TM tapentadol CII Immediate Release Tablets Now Available For Relief Of Moderate To Severe Acute Pain
Patients suffering from acute pain and healthcare professionals who treat pain have a new treatment option: NUCYNTA(TM) (tapentadol) CII immediate release tablets. This new medication for the relief of moderate to severe acute pain in patients 18 years of age or older is now available by prescription only in 50-mg, 75-mg and 100-mg tablets, announced PriCara, (R) Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. NUCYNTA(TM) binds to mu-opioid receptors and inhibits norepinephrine re-uptake. Although the exact mechanism of action is not known, these two mechanisms, which affect established pain pathways, are thought to be responsible for pain relief with NUCYNTA.
According to the CDC, 46 million Americans were told by a doctor they have arthritis, the leading cause of disability in the United States. Flexcin International, Inc., a natural supplement company offering the only joint pain remedy products with CM8™ , offers arthritis and bursitis treatment for anyone suffering from pain-related disease and injuries. The CDC also reports that the most commonly identified limitations among adults reporting a disability include walking three blocks and climbing a flight of stairs. Given the aging of "baby boomers, " the number of adults with joint pain and arthritis is likely to increase dramatically over the next 15 years.
While it is well known that excessive text messaging can result in sore thumbs, less is known about its possible effects on the neck, arms and hands. Young adults with symptoms in these parts of the body use a different technique when texting, according to a study at the Sahlgrenska Academy, University of Gothenburg, Sweden. Ergonomist Ewa Gustafsson studied mobile phone habits among 56 young adults who text message on a daily basis. Half of the subjects reported problems with the neck, arms or hands, while the other half had no such symptoms. 'Considering how much we use the small mobile phone keypads, it is important that we learn how they affect our bodies.
New Studies Presented At European Society Of Anaesthesia Further Validate Masimo PVI TM For Noninvasive And Continuous Fluid Monitoring
Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced that three new independent studies demonstrating the clinical accuracy and utility of Masimo PVI as a noninvasive and continuous measure of patient fluid status and responsiveness were presented this week at the European Society of Anaesthesiology (ESA) Annual Congress in Milan, Italy. Although fluid administration is critical to optimizing patient status and enabling end organ preservation, unnecessary fluid administration is associated with increased morbidity and mortality. Traditional invasive measurements such as central venous pressure are not reliable to predict whether a patient will benefit from fluid administration, and newer more reliable methods to predict fluid responsiveness are also invasive and costly.